200 cyclists led by former England, Crystal Palace and Wolves footballer and blood cancer survivor Geoff Thomas have completed an epic four day 500km cycle from London to Paris in aid of Cure Leukaemia, Elonex’s official Charity Partner.
The ride took place from 19th-22nd May 2016, with Adam Stockton, Managing Director at Elonex, cycling in the peloton from Greenwich Park to the Eiffel Tower.
Early reports suggest that the fundraising total from this year’s ride will surpass that of 2015, with all donations helping Cure Leukaemia continue to provide new drugs and treatments for blood cancer patients.
Cure Leukaemia CEO James McLaughlin, who took part in the ride for the second time said: “It was another hugely successful event and I hope everyone who took part had a truly memorable experience. We look set to beat the fundraising total from 2015 and I hope Team Revolution keep pushing their fundraising targets to help save more lives.”
Adam Stockton (pictured), who was part of the event’s support crew in 2015 before cycling the route this year commented: “Cycling 500km over 4 days was an incredible experience and I’m humbled to have played a part in raising funds for the life saving work Cure Leukaemia conducts. During the ride I was never far from a personal story about how leukaemia has affected lives, which, if I needed any, provided extra inspiration to get the job done.
“Having worked closely with the charity for the last couple of years I know every penny raised really does count, and continuing to fundraise for Cure Leukaemia is vital for people battling blood cancers.”
Founded in 2003 by Professor Charlie Craddock CBE, Cure Leukaemia helps to bring pioneering drug and transplant treatments to blood cancer patients throughout the Midlands. The charity helps finance the world class Centre for Clinical Haematology (CCH) at Queen Elizabeth Hospital in Birmingham, to fund life-saving clinical trials to treat patients with blood cancer who have exhausted standard treatment options. To date, Cure Leukaemia has helped to treat over 4000 patients by leveraging over £25m worth of revolutionary drugs and funding crucial research nurses to administer these trials.
Without the expert research nurses to ensure patients are constantly monitored and cared for; these trials would not run and patients would miss the opportunity to access potentially life-saving therapies. The aim of Cure Leukaemia is to raise money to fund more research nurses at centres across the Midlands and provide world-class treatment for its patients. Only by funding more nurses in more hospitals, can more leukaemia patients benefit from access to potentially life-saving treatment.
In 2016 a £3million capital fundraising campaign was announced to develop the CCH and establish the Birmingham Institute of Haematology (BIH). The BIH would double the capacity for specialist research nurse positions, world first clinical trials and leukaemia patients treated at the Centre. This development will be a focus for Cure Leukaemia’s fundraising throughout 2016.
For more information regarding Cure Leukaemia visit www.cureleukaemia.co.uk
To donate to Adam’s fundraising target, please visit www.justgiving.com/fundraising/adam-stockton